英文名稱 | Lenacapavir |GS-6207 |
---|---|
中文名稱 | 來那卡帕韋 |
CAS號 | 2189684-44-2 |
分子式 | C39H32ClF10N7O5S2 |
分子量 | 968.28 |
外觀 | White to light yellow powder |
儲存條件 | Dry, dark and at 0 - 4 ℃ for short term (days to weeks) or -20 ℃ for long term (months to years). |
英文名稱 | Lenacapavir |GS-6207 |
---|---|
中文名稱 | 來那卡帕韋 |
CAS號 | 2189684-44-2 |
分子式 | C39H32ClF10N7O5S2 |
分子量 | 968.28 |
外觀 | White to light yellow powder |
儲存條件 | Dry, dark and at 0 - 4 ℃ for short term (days to weeks) or -20 ℃ for long term (months to years). |
Lenacapavir (GS-6207) is a novel, first-in-class,long-acting and highly potent HIV-1 capsid inhibitor approved in EU on August 22, 2022 to treat HIV patients infected with multidrug-resistant virus and as a twice-yearly injectable for pre-exposure prophylaxis.